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Osteopontin (OPN) is highly expressed in demyelinating lesions in multiple sclerosis (MS) 
and experimental autoimmune encephalomyelitis (EAE). OPN is cleaved by thrombin 
into N- (OPN-N) and C-terminal (OPN-C) fragments with different ligands and functions. 
In EAE, administering recombinant OPN induces relapses, whereas treatment with 
anti-OPN antibodies ameliorates the disease. Anti-OPN autoantibodies (autoAbs) are 
spontaneously produced during EAE but have never been detected in MS. The aim 
of the study was to evaluate anti-OPN autoAbs in the serum of MS patients, correlate 
them with disease course, and recapitulate the human findings in EAE. We performed 
ELISA in the serum of 122 patients collected cross-sectionally, and 50 patients with 
relapsing–remitting (RR) disease collected at diagnosis and followed longitudinally 
for 10 years. In the cross-sectional patients, the autoAb levels were higher in the RR 
patients than in the primary- and secondary-progressive MS and healthy control groups, 
and they were highest in the initial stages of the disease. In the longitudinal group, the 
levels at diagnosis directly correlated with the number of relapses during the following 
10 years. Moreover, in patients with active disease, who underwent disease-modifying 
treatments, autoAbs were higher than in untreated patients and were associated with 
low MS severity score. The autoAb displayed neutralizing activity and mainly recognized 
OPN-C rather than OPN-N. To confirm the clinical effect of these autoAbs in vivo, EAE 
was induced using myelin oligodendrocyte glycoprotein MOG35–55 in C57BL/6 mice 
pre-vaccinated with ovalbumin (OVA)-linked OPN or OVA alone. We then evaluated the 
titer of antibodies to OPN, the clinical scores and in vitro cytokine secretion by spleen 
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inTrODUcTiOn
Multiple sclerosis (MS) is an inflammatory disease of the central 
nervous system (CNS) characterized by an autoimmune attack 
against the myelin sheaths and axons resulting in demyelination 
and axonal loss (1). MS patients display variable clinical courses; 
at onset, approximately 15% of patients display a primary-
progressive (PP) form, whereas the remainder start out with a 
relapsing–remitting (RR) form, and most of those patients switch 
to a secondary-progressive (SP) form within 10–30 years (2). An 
increasing number of disease-modifying treatments (DMTs) are 
available for RR MS, and a key challenge in therapeutic decision-
making is effective treatment stratification, given uncertain 
prognoses (3).
Data obtained in animal models and humans strongly suggest 
that osteopontin (OPN) plays a role in the pathogenesis of MS 
(4). OPN is a 60 kDa secreted phosphoprotein functioning as 
a free cytokine in body fluids or as an immobilized extracel-
lular matrix molecule in mineralized tissue (5). Its expression 
is increased in the sera of patients with several autoimmune 
diseases, including MS (6–9), and it may influence the develop-
ment of autoimmunity through its immunoregulatory and pro-
inflammatory effects. The OPN transcript is abundant in plaques 
dissected from the brains of MS patients, whereas it is absent in 
control brain tissue (10). A similar finding has been obtained in 
experimental autoimmune encephalomyelitis (EAE), an animal 
model of MS (10, 11). In blood and cerebrospinal fluid of MS 
patients, OPN levels are increased and correlate with the clinical 
stage because higher levels have been detected in RR-MS patients 
than in PP-MS and SP-MS patients (6). Moreover, in RR-MS 
patients, OPN levels increase during relapses and decrease in 
the remission phase without substantial influence by interferon 
(IFN)-β treatment (12).
Genetic analyses have associated variations of the OPN gene 
with MS (6). In this context, we found variants of the OPN gene 
that were associated with (i) increased risk for MS (an approxi-
mately 1.5-fold increase); (ii) severe disease course, with fast 
switching from a RR to a SP form and evolution of disability; 
and (iii) production of high levels of OPN because of increased 
stability of the encoded mRNA (6, 13).
In MS lesions, high OPN levels are present in the perivascular 
cuff, which surrounds the inflamed blood vessels, contains 
inflammatory lymphocytes, and is delimited by the endothelium 
and the basement membrane. At this site, OPN may play a role in 
lymphocyte recruitment into the MS lesion, which involves α4β1 
integrin, the target of natalizumab, an established DMT. During 
inflammation, thrombin acts on a cleavage site located in the 
middle of the OPN sequence, near to an arginine–glycine–aspar-
tate (RGD) motif involved in binding several integrins (14), to 
generate two OPN fragments, one N-terminal (OPN-N) and one 
C-terminal (OPN-C). OPN-C contains the CD44-binding site 
involved in the downregulation of interleukin (IL)-10 expression 
and inhibition of lymphocyte apoptosis (15). OPN-N contains 
the RGD motif and two cryptic α4β1 integrin-binding sites 
unmasked by thrombin cleavage, and it is involved in the induc-
tion of IFN-γ secretion in T cells (14, 16). The functional activity 
of the two fragments has been mostly distinguished in vitro (17), 
but the observation that, in carotid plaques of patients with 
hypertension, levels of OPN-N are higher than those of OPN-C 
suggests that the two fragments may play different roles also in 
pathologic conditions in vivo (16).
Chabas et  al. showed that OPN−/− mice were resistant to 
progressive EAE and had frequent remission; notably, myelin-
reactive T cells produce more IL-10 and less IFN-γ in these mice 
than in their wild-type counterparts (10). Moreover, treatment 
with OPN exacerbated EAE in both wild-type and, to a greater 
extent, OPN−/− mice. In OPN−/− mice, daily administration of 
OPN during the spontaneous recovery of EAE counteracted the 
ongoing remission and induced a relapse followed by a progres-
sive severe disease, leading to death (18).
We have recently shown that thrombin-mediated cleavage 
of OPN plays a role in OPN-mediated relapse induction, since 
a recombinant OPN-mutant resistant to thrombin-mediated 
cleavage was less effective than wild-type OPN in inducing the 
EAE relapse, and OPN-C was more effective than OPN-N (17).
Steinman et  al. showed that EAE induction triggered the 
production of anti-OPN autoantibodies (autoAbs), and remis-
sion occurred when their titers peaked (19). Moreover, DNA 
vaccination with a plasmid encoding OPN before EAE induction 
boosted the production of these autoAbs and ameliorated the 
chronic course of the disease. In humans, autoAbs against OPN 
have been reported in rheumatoid arthritis and osteoarthritis, and 
their serum level was inversely correlated with markers of disease 
activity (20). Moreover, passive immunization with antibodies 
against the cryptic epitope of OPN-N exerted beneficial effects 
in mouse and primate models of rheumatoid arthritis (21). These 
lymphocytes. Vaccination significantly induced antibodies against OPN during EAE, 
decreased disease severity, and the protective effect was correlated with decreased 
T cell secretion of interleukin 17 and interferon-γ ex vivo. The best effect was obtained 
with OPN-C, which induced significantly faster and more complete remission than other 
OPN vaccines. In conclusion, these data suggest that production of anti-OPN autoAbs 
may favor remission in both MS and EAE. Novel strategies boosting their levels, such as 
vaccination or passive immunization, may be proposed as a future strategy in personal-
ized MS therapy.
Keywords: osteopontin, multiple sclerosis, autoantibodies, experimental autoimmune encephalomyelitis, 
vaccination
Table 1 | clinical variables in multiple sclerosis (Ms) patients followed 
for at least 10 years.
Ms patients with 
10-year follow-up 
(n = 50)
Female, n (%) 28 (56)
Follow-up, years, mean (±SD) 12.0 (±1.2)
Age of onset, years, mean (±SD) 32.0 (±9.9)
Osteopontin (OPN) levels, pg/ml, mean (±SD) 4,952 (±3,441)
OPN autoantibody levels, optical density, mean (±SD) 0.4860 (±0.3415)
Mono-symptomatic onset, n (%) 24 (48)
Expanded disability status score (EDSS) at first relapse, 
median (min–max)
2.5 (1–7.5)
EDSS at last visit, median (min–max) 2 (0–9)
Multiple Sclerosis Severity Score, mean (±SD) 2.7 (±2.4)
N relapses at 5 years, median (min–max) 3 (1–14)
N relapses at 10 years, median (min–max) 5 (1–23)
MS course at 10 years, n (%)
 – Relapsing–remitting
 – Secondary progressive
45 (90)
5 (10)
Disease-modifying treatment, n (%) 32 (64)
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data are in accordance with reports showing the production of 
autoAbs against inflammatory cytokines in several autoimmune 
diseases and suggesting that they may play a role in counteracting 
the pathological response (22).
The aim of the research reported here was to evaluate anti-
OPN autoAbs in the serum of MS patients, to determine their 
correlation with the disease course, and to perform preclinical 
studies assessing the possible use of anti-OPN immunization 
in MS therapy. The results showed that high levels of anti-OPN 
autoAbs are displayed by RR-MS patients, especially in the 
remission phase, and may have a prognostic value at diagnosis. 
These autoAbs displayed neutralizing activity, mainly recognized 
OPN-C, and decreased disease severity in EAE.
MaTerials anD MeThODs
Patients
We enrolled two groups of MS patients diagnosed according to 
the 2001 McDonald criteria (23):
 i) a cross-sectional group of 122 patients (73 females, 49 males, 
mean age 43 ± SD 11 years). Seventy-two patients had RR-, 29 
PP-, and 21 SP-MS course. Patients were enrolled from the MS 
Centers of the Maggiore University Hospital (Novara), San 
Luigi Hospital (Orbassano, Turin), and San Raffaele Hospital 
(Milano). Patients and controls were Caucasian, Italian, and 
unrelated. Healthy controls (HCs, n = 40) did not differ in age 
and gender from the patients.
 ii) a longitudinal group of 50 bout-onset patients, recruited 
during a prospective study aimed at identifying predictors of 
disease progression (24). We included patients still on regular 
follow-up 10  years after diagnosis, and of whom we stored 
serum at time of diagnosis. Clinical data collected in the 
prospective cohort included age at onset, expanded disability 
status score, number of relapses updated at 10 years, and any 
DMTs. We also calculated the Multiple Sclerosis Severity 
Score (MSSS) at 10 years for each patient (25). DMTs included 
both first line (beta-IFN and glatiramer acetate) and second 
line treatments (azathioprine, natalizumab, and fingolimod). 
Clinical features of the longitudinal cohort are shown in 
Table 1. Patients were enrolled from the MS Centers of the 
Maggiore University Hospital (Novara) and Santa Croce e 
Carle Hospital (Cuneo).
Written informed consent was obtained from all subjects, and 
analyses were conducted according to the Declaration of Helsinki 
and approved by the ethical committee of University Hospital of 
Novara (reference no. CE1804).
cloning and Production of OPn 
recombinant Proteins
cDNA coding for the human and murine OPN full-length 
(OPN-FL), OPN-N, and OPN-C were cloned by PCR into a 
pUCOE expression vector as previously described (17) and 
stably transfected in Chinese hamster ovary cells (CHOs). Cell 
supernatants were collected, and the recombinant proteins 
were purified on a nickel-nitrilotriacetic agarose resin (Qiagen, 
Limburg, Netherlands) and characterized by Western blotting 
using either an antibody directed against the His tag (Tetra-His 
Antibody, Qiagen, Valencia, CA, USA) or an anti-OPN antibody 
directed against an epitope located in the N- or C-terminal half 
of the molecule: SPP1 polyclonal antibody (Invitrogen) and 
polyclonal anti-osteopontin antibody (Millipore, Billerica, MA, 
USA), respectively (17).
Detection of anti-OPn autoabs by elisa
Serum anti-OPN autoAbs were assessed by a custom-made 
immunoenzymatic assay (ELISA). Briefly, polystyrene ELISA 
Maxi-Sorp plates (Nunc, Roskilde, Denmark) were coated by 
overnight incubation at 4°C with 2 μg/ml of the FL-, N-, or C-OPN 
(recombinant OPN) as capture protein. Non-specific binding 
was blocked by 1 h incubation with 0.3 ml of 0.05% Tween 20 
in phosphate buffered saline (PBS), pH 7.4. Each serum sample 
(0.1  ml diluted 1:100 in 0.05% Tween 20 in PBS, pH 7.4) was 
added in duplicate and incubated for 2 h at 37°C. After 10 washes 
with 0.05% Tween 20 in PBS, antibody binding was revealed by 
peroxidase-conjugated goat anti-human immunoglobulin (Ig)G 
(dilution 1:4.500) (Dako, Glostrup, Denmark). The results were 
expressed as optical density at 450 nm.
immune complexes Dissociation
Heat-mediated dissociation of immune complex was obtained 
by boiling diluted serum samples and each point of the OPN 
standard curve for 5 min. After 4 min chill on ice, samples were 
loaded into a 96-well plate for ELISA evaluation, and the results 
were compared to non-boiled samples. Concentration of OPN 
was measured by commercial ELISA according to the manu-
facturers (R&D system, Minneapolis, MN, USA). Absorbance 
was detected with a microplate reader (Bio-Rad, Hercules, 
CA, USA), and the I-smart program was used to calculate the 
standard curve.
4Clemente et al. AutoAbs to OPN in MS and EAE
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activation-induced cell Death (aicD)
Activation-induced cell death was evaluated on T  cell lines 
obtained by activating PBMC with phytohemagglutinin (PHA) 
at days 0 (1 μg/ml) and cultured in RPMI 1640 medium + 10% 
FBS + IL-2 (2 U/ml) (Sigma, Saint Louis, MO, USA) for 6 days. 
In the AICD assay, cells (5 ×  104/well) were cultured in wells 
coated with anti-CD3 mAb (OKT3, 10 μg/ml) with RPMI + 5% 
FBS + IL-2 (1 U/ml) in the presence or absence of recombinant 
OPN (1 μg/ml). AICD was performed also in the presence of 
IgG purified (10  μg/ml), with protein G sepharose resin (Ge 
Healthcare, Piscataway, NJ, USA), from three patients displaying 
high levels of anti-OPN autoAbs. The control was done by using 
a commercial goat anti-OPN-neutralizing Ab (R&D system). 
Live cells were then counted in each well using the trypan blue 
exclusion test. Assays were performed in triplicate and results 
were expressed as relative cell survival % calculated as follows: 
(total live cell count in the assay well/total live cell count in the 
respective control well) × 100.
Mouse Vaccination and eae induction
Mouse OPN-FL, OPN-N, and OPN-C were cross-linked to ovalbu-
min (OVA) (Sigma) with glutaraldehyde (Sigma) as reported (26).
The experimental protocol and animal handling were approved 
by the ethical committee of the University of Piemonte Orientale 
(reference no. 10821, 10/2013), Novara, Italy. Four-week-old 
female C57BL/6 mice (n = 8/10 each group) were anesthetized 
with isoflurane and immunized weekly intra-peritoneally for 
4 weeks with 10 μg of OPN-FL/OVA, 5 μg of OPN-N/OVA or 
OPN-C/OVA or 10 μg of OVA in 50 μl glycine buffer, 0.15 M, 
pH 5.7, and 50 μl of incomplete Freund adjuvant (Sigma). EAE 
was induced 1  week after the last immunization with 200  μg 
of MOG35–55 peptide (Espikem, Florence, Italy) and scored as 
reported (22).
Mouse splenocytes were purified and cultured in the pres-
ence or absence of 10 μg/ml MOG35–55 as reported. After 5 days, 
levels of IFN-γ, IL-10, IL-4, and IL-17 were evaluated by ELISA 
(Biolegend, San Diego, CA, USA) in the supernatants and cell 
proliferation by incorporation of [3H] thymidine (27).
recombinant mab Production
OPN full-length was used as a target for selecting antibodies 
from a phage display Ab library as previously described (28). The 
selection was performed in immuno tubes coated with recom-
binant protein incubated overnight at 4°C in PBS. The panning 
procedure was repeated twice. In total, 96 random clones were 
selected, and a specific positive clone to OPN-C was identified 
using phage ELISA. The positive scFv clone was converted into 
the human scFv–Fc format by subcloning into the pMB-SV5 
(29) vector containing the human hinge–CH2–CH3 domain. For 
antibody production, CHOs cell lines were transfected and stable 
clones obtained through selection with hygromicin B (500 μg/
ml, Invitrogen). The scFv–Fc molecules were purified from 
cell culture supernatant using a HiTrap protein G column (GE 
Healthcare). After elution, the preparations of purified scFv–Fc 
were dialyzed in BupHTM phosphate buffer (Thermo Fisher 
Scientific, Waltham, MA, USA), aliquoted, and stored at −80°C. 
The selected mAb was tested by ELISA for its capacity to bind 
both human and mouse OPN-C and OPN-FL. The mAb was also 
tested during EAE in a passive immunization protocol.
statistical analysis
The non-parametric Mann–Whitney U-test was used to compare 
autoAb levels in the different groups of subjects; the Pearson cor-
relation coefficient was used to test correlations. The Wilcoxon 
test was used to compare autoAbs to OPN-C and OPN-N in 
each subject; the Friedman ANOVA test for repeated measures 
followed by Dunn’s multiple comparison was used to compare 
the daily clinical EAE score (GraphPad Software, San Diego, 
CA, USA). p Values below 0.05 were considered statistically sig-
nificant. The statistical analyses were performed with GraphPad 
Instat software (GraphPad Software).
resUlTs
Detection of anti-OPn autoabs in 
Ms Patients
Serum anti-OPN autoAbs were evaluated in 122 cross-sectional 
MS patients (72 RR, 29 PP, 21 SP) and 40 HCs by ELISA using 
OPN-FL. Anti-OPN autoAbs were detected in the serum of 
both patients and controls, but the titer was significantly higher 
in patients than in the controls (0.278 vs 0.147, p  <  0.0001; 
Figure 1A). Analysis of the different MS clinical forms showed 
that autoAb levels were significantly higher in RR patients in 
relapse or remission than in SP and PP patients and HCs (0.289 
vs 0.168 vs 0.169 vs 0.147; Figure 1A). By contrast, no differences 
were detected among SP and PP patients and HCs. Moreover, in 
RR-MS patients, the autoAb levels were higher in those in remis-
sion than in those in relapse (0.368 vs 0.237; p < 0.01), and they 
displayed an inverse correlation with disease duration at the time 
of blood withdrawal, which was not evident in the other disease 
courses (Figure 1B). These data suggest that the inflammatory 
phase of the disease, displaying high levels of OPN, drives pro-
duction of anti-OPN autoAbs.
anti-OPn-Fl autoabs at Diagnosis 
and clinical Outcome
The second cohort of patients comprised 50 consecutive bout-
onset patients followed up for more than 10 years whose serum 
was withdrawn at diagnosis. In these patients, we evaluated the 
serum levels of anti-OPN autoAbs and determined their correla-
tion with the clinical outcome after 10 years. The results showed 
a direct correlation between autoAb levels at diagnosis and the 
number of relapses occurring in the following 10 years (r = 0.542, 
p < 0.0001; Figure 2A). By contrast, no correlation was found with 
the MSSS after 10 years (r = −0.029, p = 0.837). Moreover, the 
autoAb levels were higher in patients who subsequently received 
DMTs (n = 31) than in those who remained untreated (n = 19, 
p <  0.0001; Figure  2B). Accordingly, all patients subsequently 
treated (n = 31) displayed levels higher than the 75th percentile 
of HC values, whereas most untreated patients (n = 12/19, 63%) 
displayed levels lower than this cutoff. Using the 75th percentile of 
HC values as a cutoff in untreated patients, we found that the MSSS 
FigUre 1 | anti-OPn autoantibodies (autoabs) are increased in relapsing–remitting (rr) patients compared with secondary-progressive (sP) and 
primary-progressive (PP) patients and healthy controls (hcs). (a) AutoAbs to osteopontin (OPN) in multiple sclerosis (MS) patients and HCs. AutoAbs 
detected by ELISA using OPN full-length as the capture protein. In the left panel, black triangles mark MS patients and white triangles the HCs. In the right panel, 
patients are stratified according to their clinical form at the time of blood withdrawal. Dark gray triangles: RR-relapse MS patients; light gray triangles: RR-remission 
MS patients; gray circles: SP-MS patients; gray diamonds: PP-MS patients; boxes: interquartile range with medians. p Values were calculated with the Mann–
Whitney U-test. The horizontal lines indicate the 75th (dashed line) and 95th (continuous line) percentiles of the HCs. (b) Inverse correlation between autoAbs to 
OPN and disease duration in RR patients (Pearson correlation test) (*p < 0.01, **p < 0.001, ***p < 0.0001).
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after 10 years was significantly lower in patients with low autoAb 
levels (n = 12) than in those with high levels (n = 7) (median 
1.01, range 0.64–1.53 vs 3.25, 1.90–4.3, p =  0.020; Figure 2C). 
By contrast, when the cutoff was set at the 95th percentile of 
HC values in treated patients, the MSSS after 10 years was lower 
in those with high autoAb levels at diagnosis (n =  15) than in 
those with low levels (n = 16) (median 1.70, range 0.96–2.78 vs 
2.54, 2.09–6.18, p =  0.030; Figure 2C). Consistently, we found 
that autoAb levels and the MSSS displayed a significant inverse 
correlation in treated patients (r = −0.374, p = 0.038; Figure 2D). 
Finally, no difference in number of relapses at 10 years was found 
on comparing both treated and untreated patients with different 
autoAb levels (data not shown).
In Vitro autoabs characterization
Since serum contains both OPN and anti-OPN autoAbs, these 
may react to form immune complexes in  vivo, thus block-
ing the cytokine activity and facilitating its removal from the 
bloodstream. To assess this possibility, we evaluated the amount 
of OPN in the sera before and after heat-mediated immune 
complexes dissociation. The results showed that heat increased 
the amount of OPN detected in all of the tested sera (Figure 3A). 
This was not ascribable to unmasking of cryptic epitopes by heat, 
since boiling did not increase the amount of OPN detected in the 
standard curve by our ELISA (data not shown).
Since we had previously demonstrated that OPN inhibits AICD 
(17), we used this test to investigate the autoAbs-neutralizing 
properties on OPN biological activity. AICD was induced in 
PHA-activated PBMC from healthy donors in the presence and 
absence of OPN-FL and each of three preparations of IgG purified 
from patients displaying high levels of anti-OPN autoAbs (>75th 
percentile of the controls). Anti-human OPN polyclonal antibod-
ies were used as positive control of OPN-neutralizing antibodies. 
The results showed that all IgG preparations were able to neutral-
ize the protective effect of OPN-FL on AICD at the same level as 
the anti-OPN-neutralizing Ab (Figure 3B).
FigUre 2 | autoantibodies (autoabs) to osteopontin (OPn) at diagnosis predict therapeutic benefits and a reduced Multiple sclerosis severity score 
(Msss). (a) Direct correlation between anti-OPN autoAbs and the number of relapses occurring over 10 years (Pearson correlation test). (b) Anti-OPN autoAbs in 
patients not receiving (circles) or receiving (diamonds) disease-modifying treatments (DMTs). The horizontal lines indicate the 75th (dashed line) and 95th (continuous 
line) percentiles of the healthy controls. Low expressors and high expressors of each group are shown in pale color and in dark color, respectively. (c) MSSS in 
patients with or without DMTs. Low expressors are shown in pale color; high expressors are shown in dark color, as in the previous panel. (D) Negative correlation 
between autoAbs to OPN and the MSSS in the treated group (Pearson correlation test) (*p < 0.05, ***p < 0.0001).
6
Clemente et al. AutoAbs to OPN in MS and EAE
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 321
autoabs to OPn-c are higher than Those 
to OPn-n in Ms sera
To map the epitopes recognized by the autoAbs, we selected sera 
from 30 RR, 10 PP, and 10 SP patients displaying high levels 
(>75th percentile of the controls) of anti-OPN autoAbs and used 
the appropriate ELISA to compare their ability to recognize either 
OPN-C or OPN-N. Figure 4 shows that all sera recognized both 
OPN-N and OPN-C, but the latter was always more highly rec-
ognized than the former. Moreover, the levels of autoAbs against 
OPN-C were higher in RR than in PP and SP, whereas those 
against OPN-N were higher in RR and SP than in PP (Figure 4).
active immunization against OPn-c 
Protects Mice from eae
To assess the effect of the anti-OPN response in vivo, C57BL/6 
mice were immunized four times with 10 μg of either mouse 
OPN-FL or OPN-N or OPN-C cross-linked to OVA. Then, EAE 
was induced with MOG35–55 1 week after the last immunization.
The serum levels of anti-OPN autoAbs were evaluated by 
ELISA using mouse OPN-FL immediately before the first 
immunization (−T32), at each immunization point (−T24, 
−T16, −T8), immediately before EAE induction (T0), at three 
points during the relapse (T16, T23, T29), and in the remission 
phase (T41). Figure 5A shows that all OPN vaccinations induced 
anti-OPN autoAbs detectable at the time of the fourth immuni-
zation (−T8) but, after 1 week (T0), these autoAbs remained at 
low levels in the mice vaccinated with OPN-N, while in those 
vaccinated with either OPN-FL or OPN-C, they increased to a 
maximum at the peak of disease (T29) and then decreased during 
the remission phase (T41).
Analysis of the course of EAE showed that the onset of the dis-
ease was delayed and its severity reduced by all OPN vaccinations, 
because the mean clinical score was 1.64 ±  0.14 (mean ±  SE) 
in control mice vaccinated with OVA, compared to 1.04 ±  0.1 
(p < 0.001), 1.13 ± 0.11 (p < 0.001), and 0.81 ± 0.09 (p < 0.001) 
in those vaccinated with OPN-FL, OPN-N, and OPN-C, respec-
tively. Moreover, mice vaccinated with OPN-C displayed faster 
and more complete remission than those in the other groups 
(Figure 5B).
To analyze the effect of OPN immunization on the anti-
MOG35–55 T cells response, spleen lymphocytes were obtained at 
FigUre 3 | autoantibodies (autoabs) to osteopontin (OPn) in serum 
of multiple sclerosis (Ms) patients form immune complexes and 
neutralize OPn activities. (a) Heat-mediated dissociation of immune 
complexes increases the amount of OPN in the sera of MS patients as 
detected by ELISA. Each symbol represents serum from a different patient. 
(b) AutoAbs to OPN reverse inhibition of activation-induced cell death (AICD) 
mediated by OPN, by neutralizing its effect. AICD was induced by treating 
phytohemagglutinin-activated PBMC cell cultures with anti-CD3 mAb (black 
histogram) and cell survival detected 18 h later; results are expressed as 
relative cell survival % by setting 100% on the cultures performed in the 
absence of the anti-CD3 mAb and their means (dashed line). Histograms 
represent AICD in the presence of recombinant OPN (white), a commercial-
neutralizing antibody to OPN (dark gray), or serum of three high-expressor 
patients (s1, s2, and s3).
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T29 and cultured for 5  days in the presence of MOG35–55. Cell 
proliferation was then assessed by [3H] thymidine uptake, and 
levels of IFN-γ, IL-4, IL-17A, and IL-10 were evaluated in the 
culture supernatants by ELISA. Cells from mice vaccinated with 
either OPN-FL or OPN-C produced lower amounts of IL-17A 
and IFN-γ than those vaccinated with either OPN-N or OVA 
(Figure 5C). By contrast, proliferation (Figure 5C) and secretion 
of IL-10 and IL-4 were not significantly different in the different 
groups of mice (data not shown).
Passive immunization with an anti-OPn-c 
mab reduces Disability in eae
To assess the in vivo effect of the human anti-OPN autoAbs, we 
produced a human recombinant mAb that was selected according 
to its capacity to bind human or mouse OPN-C, but not OPN-N 
(Figure 6A), and to neutralize the human OPN-mediated inhi-
bition of AICD (Figure  6B). The anti-OPN-C mAb or control 
human IgG were injected i.p. in mice at T5, T7, and T9 after EAE 
induction. Analysis of the disease scores showed that disability 
was substantially lower in the mice treated with the mAb than in 
the control mice in the initial disease phases until T9 (Figure 6C). 
Subsequently, in the mAb-treated mice, the scores increased 
abruptly, almost reaching the scores of the control mice from 
T10 to T13. We then performed another set of four injections of 
the mAb (or IgG in the control mice) at T13, T14, T15, and T16. 
In the mice treated with the mAb, the treatment was followed 
by a decrease of the disease scores until T18, after which the 
scores again gradually increased and almost reached those of the 
control mice at T21. Subsequently, both groups of mice developed 
a similar remission (Figure 6C).
To assess whether the short-lasting effect of the mAb was due 
to production of antibodies against its human determinants, we 
searched for these reactive antibodies in the serum of the mice 
at T4, T12, and T24 using ELISA plates absorbed with the mAb. 
Results showed that the anti-mAb response was detectable at T12 
and T24, and it was higher in the mice treated with the mAb than 
in those treated with human IgG (Figure 6D; p < 0.05).
DiscUssiOn
This study has shown that patients with RR MS display high levels 
of anti-OPN autoAbs, and these levels are more elevated in remis-
sion than in relapse phase. By contrast, these increased levels are 
not detected in patients with progressive forms of MS, i.e., PP 
and SP (Figure 1). Moreover, in mouse EAE, vaccination with 
OPN, boosting production of anti-OPN autoAbs, ameliorates the 
disease course (Figure 5). These data suggest that production of 
anti-OPN autoAbs may favor remission in both MS and EAE.
We analyzed correlations between the anti-OPN autoAb levels 
evaluated at diagnosis and MS clinical course in a prospective 
cohort of RR patients (24). We found opposite behaviors of OPN 
autoAbs in patients receiving or not DMTs: a lower disability 
over 10 years was correlated with high anti-OPN autoAb levels 
at diagnosis in the former and with low levels in the latter group 
(Figure  2). Altogether, these findings may have two different, 
albeit not conflicting, explanations.
First, anti-OPN autoAbs may mark the inflammatory phase of 
MS. In fact, anti-OPN autoAb levels not only showed an inverse 
correlation with disease duration but were also higher (0.46 vs 
0.26, p = 0.0074) in longitudinal RR patients at diagnosis than in 
cross-sectional RR patients, a portion of whom were tested long 
after diagnosis, when relapses are less frequent. In cross-sectional 
RR patients, the autoAb levels were higher during remission 
FigUre 4 | autoantibodies (autoabs) to OPn-n and OPn-c fragments in multiple sclerosis (Ms) patients with different clinical forms. AutoAbs 
detected by ELISA using either OPN-N (white triangles) or OPN-C (black diamonds) as the capture protein in 30 relapsing–remitting (RR) (a), 10 primary-progressive 
(PP) (b), and 10 secondary-progressive (SP) (c) MS patients. Boxes: interquartile ranges and medians (Wilcoxon test) [*p < 0.05, **p < 0.001, ***p < 0.0001, 
#p < 0.05 vs RR patients (Mann–Whitney U-test)].
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than during relapse, thus suggesting that anti-OPN autoAbs are 
increased by the OPN peak that occurs during relapse. Indeed, 
high levels were detected in active patients, i.e., both longitudinal 
RR patients who had subsequently undergone DMTs and those 
who had not received treatments despite the unfavorable long-
term outcome. By contrast, patients with less active disease, i.e., 
patients not starting DMTs and showing lower MSSS at 10 years, 
displayed lower antibodies at diagnosis (Figure 2). Overall, these 
data suggest that high levels of anti-OPN autoAbs at diagnosis 
may help in identifying active patients requiring DMTs.
Second, in patients with active disease, anti-OPN autoAbs 
may antagonize deleterious activities of OPN involved in MS 
pathogenesis and cooperate with DMTs to counteract disease 
progression. These data are in line with those in EAE in which 
vaccination with OPN, boosting production of anti-OPN auto-
Abs, ameliorates the disease course and improves remission, 
as shown also by Steinman et al. (19). Thus, the production of 
anti-OPN autoAbs may favor remission in both MS and EAE. 
This model is summarized in Figure 7.
Because the anti-OPN autoAbs were also detected at low levels 
in the controls, they may be a physiologic response intended to 
downmodulate the immune response, which is a mechanism that 
may be shared by other inflammatory cytokines (22). In line with 
this possibility, we show that the anti-OPN autoAbs are able to 
neutralize the OPN biologic activity, as detected by their ability 
to inhibit the OPN-mediated protection on lymphocyte AICD 
(Figure 3) (17). This neutralization may partly depend on OPN 
sequestration into immune complexes which may prevent OPN 
from binding to its cellular receptors and promote OPN removal 
from the inflamed tissue/bloodstream through the activity of the 
immune complexes clearing system. However, since the anti-
OPN response is polyclonal, it is also possible that some autoAbs 
have direct blocking effects on the several OPN-binding sites for 
cellular receptors. Discriminating the role of these binding sites 
and of molecular and cellular interactions is crucial for designing 
a specific therapy to target the portion performing the pathogenic 
function while preserving the physiologic activity of the others.
The notion of the protective effect of autoAbs in autoimmune 
diseases is also supported by clinical experience with B-cell-
depleting treatments. While use of anti-CD20 antibodies, such as 
rituximab and ocrelizumab, is considered an important therapeu-
tic strategy in MS (30), two randomized controlled clinical trials 
with atacicept in MS and optic neuritis were discontinued for 
significant disease worsening in the treatment compared to the 
placebo arms (31, 32). A possible explanation for this discrepancy 
between the two B-cell-depleting treatments is that anti-CD20 
FigUre 5 | Vaccination against osteopontin (OPn) induce autoantibodies (autoabs) to OPn and protects mice from experimental autoimmune 
encephalomyelitis (eae). (a) Anti-OPN autoAb levels in vaccinated EAE mice and scheme of the vaccination protocol. Four-week-old female C57BL/6 mice were 
immunized once a week for 4 weeks with either OPN full-length (OPN-FL) (white squares), OPN-N (white triangles), and OPN-C (white circles) cross-linked to 
ovalbumin (OVA) or OVA alone as a control (black diamonds). EAE was induced with MOG35–55 1 week after the last immunization. Black triangles indicate blood 
draws to evaluate OPN autoAbs. The error bars represent the SE for each point [**p < 0.01 OPN-FL and OPN-C vs OVA; #p < 0.01 OPN-FL and OPN-C vs OPN-N 
(Mann–Whitney U-test)]. (b) Clinical scores of EAE in mice vaccinated as described in panel (a). The error bars represent the SE for each point. A non-parametric 
ANOVA test was used to compare the clinical scores (***p < 0.001 OPNs vs OVA; ##p < 0.001 OPN-C vs OVA, OPN-FL, OPN-N). (c) In vitro response to MOG35–55 
of spleen lymphocytes from EAE mice vaccinated with OPNs. T cell proliferation, interleukin (IL)-17, and interferon (IFN)-γ secretion were measured in spleen 
lymphocyte cultures stimulated with MOG35–55. Spleen lymphocytes were obtained at day 29 after EAE induction, from mice vaccinated with either OVA or OPN-FL, 
OPN-N, or OPN-C. Histograms represent the mean ± SE from six mice [*p < 0.05 vs OVA (Mann–Whitney U-test)].
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antibodies relatively spear plasma cells, thus allowing the 
production of protective antibodies. On the contrary, atacicept 
significantly reduces serum Ig concentrations, mature B cells but 
also plasma cells (33).
A major objective at MS diagnosis is to act at the early inflam-
matory stage, delaying disease progression and development of 
disability. Patients with RR MS may benefit from DMTs showing 
different degrees of both efficacy and side effects. Personalized 
treatment is a key challenge in decision-making with regard to 
MS because of the shortage of reliable markers of individual 
disease prognosis. Therefore, OPN and anti-OPN autoAbs 
might be valuable tools in this scenario. OPN levels have been 
analyzed extensively in MS, as biomarkers of disease activity 
and DMTs effectiveness (34, 35), and displaying correlations 
with clinical outcome. These findings have been useful to depict 
the immunopathological role of OPN in MS, but not to evaluate 
MS prognosis because of the wide variability of the OPN levels 
in different clinical conditions and experimental settings (36, 
37). These inconsistencies may be related to the numerous clini-
cal conditions that may influence OPN levels, the difficulty of 
detecting the different OPN forms (depending on glycosylation, 
phosphorylation, and proteolytic cleavage), and the variable 
amount of OPN included in the immune complexes with its 
autoAbs. Similarly, also detection of anti-OPN autoAbs may be 
misleading because they may be part of the immune complexes 
and vary in their ability to neutralize the multiple functions of 
FigUre 7 | high anti-OPn autoantibodies (autoabs) levels in relapsing–
remitting (rr) multiple sclerosis (Ms) at diagnosis mark active disease 
and support the efficacy of disease-modifying treatments (DMTs). High 
levels of autoAbs are displayed by patients with active disease including both 
those who received DMTs and those who did not, despite the subsequent 
disease progression, which might be associated with the high inflammation 
and high osteopontin (OPN) levels. However, in the treated patients, the 
autoAbs may cooperate with DMTs to slow down progression, whereas they 
are not sufficient to control the disease in the untreated patients.
FigUre 6 | Passive immunization using an anti-OPn mab reduces disability in experimental autoimmune encephalomyelitis (eae). (a) ELISA testing of 
the selected mAb, showing its capacity to bind to both human and murine OPN-C, OPN-FL but not to OPN-N. (b) The selected mAb neutralizes osteopontin 
(OPN)-mediated protection from activation-induced cell death (AICD). AICD was induced as described in the legend of Figure 3. The white histogram represents AICD 
in the presence of recombinant OPN and the gray histogram AICD in the presence of both OPN and the selected mAb, neutralizing it. (c) Clinical scores of EAE in 
mice treated with the selected mAb (black diamonds) or with a control immunoglobulin (Ig)G (white squares). The error bars represent the SE for each point. Black 
triangles mark the days of treatment and gray boxes the significantly protected days. A non-parametric ANOVA test was used to compare the clinical scores. 
(D) ELISA detecting antibodies against the human determinants of the selected mAb (black) or its isotype control (white), in the serum of treated mice. The anti-mAb 
response was detectable at T12 and T24 and it was higher in the mice treated with the mAb than in those treated with human IgG [*p < 0.05 (Mann–Whitney U-test)].
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OPN. It is possible that the best approach would be the parallel 
evaluation of both free and immune complexes-bound OPN and 
anti-OPN autoAbs.
Intriguingly, the anti-OPN response recognized OPN-C better 
than OPN-N in all patients, which may mark both quantitative 
(i.e., different amounts) and qualitative (i.e., different affinities) 
differences of the autoAbs produced against the two fragments 
(Figure 4). The focus on OPN-C was further noted by the EAE 
experiments because vaccination with OPN-C resulted in the 
greatest induction of anti-OPN autoAbs, ameliorating disease 
progression, particularly in terms of inducing disease remission 
and decreasing the autoantigen-driven production of IFN-γ 
and IL-17 (Figure 5). Moreover, passive immunization with the 
human anti-OPN-C recombinant antibody ameliorated the dis-
ease course (Figure 6). These data identified a role for the CD44-
binding site displayed by OPN-C, which is intriguing because 
CD44 is involved in EAE by favoring the homing and survival 
of the autoimmune T cells, and by increasing IL-17A and IFN-γ 
production and decreasing IL-10 production (34–42). Moreover, 
data in the literature show that OPN stimulates IL-17A and IFN-γ 
production and inhibits IL-10 production in EAE and MS (15).
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The critical role of OPN-C is surprising because the presence 
of the binding sites for α4β1 would instead direct the attention to 
OPN-N because α4β1 is involved in the CNS homing of T cells 
and is the target of the anti-MS drug natalizumab. However, it is 
noteworthy that our data indicate that OPN-N also plays a role 
in EAE, because vaccination with OPN-N ameliorated disease 
progression. Moreover, when we analyzed the autoAbs to OPN-C 
and OPN-N in the longitudinal group of RR-MS patients at diag-
nosis, we could not confirm the clinical correlations detected on 
the total anti-OPN autoAbs, which highlights the importance of 
the global response to OPN (data not shown).
In the EAE experiments, we used a prophylactic vaccina-
tion protocol in which immunization was performed before 
EAE induction. This procedure would be of limited benefit in 
humans, who would instead benefit from a therapeutic vac-
cination performed after the onset of disease. However, even 
a therapeutic vaccination would be problematic in humans 
because of the concern about inducing an uncontrollable anti-
OPN response. By contrast, a possible approach would be to use 
anti-OPN- neutralizing antibodies, since we show that they can 
ameliorate EAE disability when administered in different phases 
of the disease. In our model, the effect was short-lasting, but this 
was probably due to the high anti-drug response elicited by the 
human mAb used in these experiments.
Osteopontin has pleiotropic activities in the immune 
response because it acts as a chemoattractant for inflamma-
tory cells, supports differentiation of proinflammatory T  cells 
and antibody production by B  cells, and increases survival of 
activated lymphocytes and inflammatory cells (4, 39, 40, 43, 44). 
Discriminating the role of each fragment in these functions and 
in MS pathogenesis is crucial for designing a specific therapy 
to counteract only the most pathogenic fragment and function 
while preserving the physiologic activity of the others. This 
work is a proof of concept that drugs targeting OPN-C may be 
proposed for MS therapy.
We have shown that anti-OPN autoAbs are found at high levels 
in RR-MS patients during the remission, and that they influence 
MS evolution and prognosis in association with DMTs. Novel 
strategies boosting their levels, such as vaccination or passive 
immunization, may be proposed as a future strategy in personal-
ized MS therapy.
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